McKechnie Duncan
CIK 0002062139
EVP, Chief Commercial Officer
Filings
7
Latest Mar 13, 2026
Issuers covered
1
Showing
7 of 7
Page 1
Track record
4 of 4 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 4 | 100% | +10.3% | +10.3% | +11.4% | +9.1% |
| 90 days | 3 | 100% | +10.2% | +9.8% | +11.0% | +9.8% |
| 180 days | - | - | - | - | - | - |
| 365 days | - | - | - | - | - | - |
Issuers
Companies where McKechnie Duncan has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc / Ma | 7 | Mar 13, 2026 |
All filings
7 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|